Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Precision Assays for Next-Gen RNA Therapeutics

PROVEN INTELLIGENCE IN RNA THERAPEUTIC BIOANALYSIS.

Precision Assays for Next-Gen RNA Therapeutics

Precision Assays for Next-Gen RNA Therapeutics: Bridging Clinical Intent with Commercial Reality

CELL & GENE | RNA | BIOLOGICS

A stylized rendering of a DNA double helix on the left side of a light blue gradient background.

Executive Summary

The bioanalytical strategy for RNA therapeutics, particularly those using lipid nanoparticle (LNP) delivery systems, cannot rely on repurposed assay frameworks. A successful program requires a phase-appropriate, modality-specific approach to quantify payload delivery, measure biological activity, and characterize the immune response. This demands a deep understanding of the interplay between the LNP carrier and the RNA payload to generate data that withstands global regulatory scrutiny and minimizes clinical risk.

Frequently Asked Questions

What are the primary bioanalytical challenges specific to RNA Therapeutics programs?

For RNA Therapeutics, the key challenges involve developing distinct, qualified assays for both the LNP delivery vehicle and the RNA payload. This includes quantifying non-target tissue biodistribution, assessing the potential for innate immune stimulation by the LNP or RNA, and developing robust potency assays that accurately measure protein expression (for mRNA) or target knockdown (for siRNA) in relevant biological matrices.

How do regulatory agencies like the FDA and EMA view biodistribution studies for Lipid Nanoparticle (LNP) therapy?

Global regulators expect comprehensive biodistribution data that characterizes the tissue localization, persistence, and clearance of both the lipid components and the RNA payload. A tailored strategy is required to provide this data, often using a combination of qPCR for the RNA and LC-MS/MS for the lipids, to build a complete safety and activity profile.

What is the typical timeline for developing GxP-compliant, clinical-grade assay development for a novel RNA therapeutic?

The timeline is program-dependent, but developing and validating robust bioanalytical methods under GxP conditions is a foundational step for enabling toxicology studies and first-in-human trials. Proactive assay development, integrated with the preclinical plan, aligns with an 18-24 month timeline to IND submission.

A standard, one-size-fits-all preclinical testing template does not exist for RNA therapeutics. The transient nature of the payload and the complex biology of LNP delivery systems necessitate a bioanalytical strategy built from first principles, tailored specifically to the asset modality and target indication.

The central questions that drive a program forward are bioanalytical in nature:

  • How much of the LNP and RNA payload reaches the target tissue versus non-target tissues?

  • Is the expressed protein functional, or is the target gene effectively silenced?

  • What is the character and duration of the immune response to the lipid carrier or the RNA itself?

  • How does the formulation impact these biological outcomes?

Translating Formulation Science into Clinical Data

Advances in formulation science directly impact bioanalytical requirements. Research into novel delivery systems, such as degradable branched lipidoids, demonstrates that specific chemical modifications can significantly enhance the efficiency of mRNA delivery to target organs like the liver (PMID: 38409275). This progress underscores the need for bioanalytical methods with sufficient sensitivity and precision to measure these performance improvements. An assay that can differentiate the biodistribution and protein expression profile of an enhanced LNP formulation versus a standard one provides the definitive data needed to justify clinical progression.

Our work with partners, including our collaboration with Moderna on its mRNA platform, is grounded in this philosophy. The core team of principal scientists and study directors at Franklin Biolabs, which launched formally in 2024, has maintained a 100% successful IND rate since 2019 by developing these types of bespoke analytical solutions.

A close-up, blue-toned image of scientific glassware, featuring vials placed in a dish filled with clear, spherical beads, suggesting a laboratory or research setting.

A GxP-Compliant Framework for Global Submissions

Our >100,000 sq ft facilityis equipped to execute these complex assays under a unified GxP framework, ensuring data integrity for harmonized IND and IMPD submissions. We develop and qualify assays in a phase-appropriate manner, providing the robust characterization required by international regulatory bodies. This integrated approach is a component of our comprehensive Bioanalytical Services, designed to support next-generation therapeutics from discovery through clinical evaluation.

Bioanalytical Endpoint mRNA Therapeutics siRNA/gRNA Therapeutics
Primary Potency Protein expression level & activity Target gene transcript knockdown
Pharmacokinetics (PK) LNP lipid & RNA payload clearance LNP lipid & RNA payload clearance
Biodistribution Quantification in target & non-target tissues Quantification in target & non-target tissues
Immunogenicity Anti-PEG antibodies, innate immune response Anti-PEG antibodies, innate immune response
Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities